Olympus will use the 3DExperience platform to develop its medical devices.
Olympus Technologies Singapore Pte Ltd., an endoscope manufacturer, has selected Dassault Systèmes' 3DExperience platform to develop its medical devices. The new “Licensed to Cure” industry solution experience will be deployed to create a single environment, allowing to eliminate scattered processes and data, and to “embed” regulations as an asset, optimizing quality and compliance.
Olympus Technologies Singapore has standard operating procedures in developing engineering and software system documentation for their medical device manufacturing. “Licensed to Cure” will help them simplify those procedures by providing a single source of information to always get relevant, up-to-date information and establish true collaboration with the same, accurate set of product data. In addition, Olympus Technologies Singapore will be able to reduce new product time to market and streamline regulatory filings by creating an end-to-end, traceable and compliant product development process directly linked to quality management.
“Dassault Systèmes’ 3DExperience platform gives us centralized control and management of all product lifecycle information, enabling real time sharing and collaboration for all functions,” says Lim HN, managing director, Olympus Technologies Singapore. “Being able to combine engineering, quality, and regulatory compliance business processes, we have moved closer towards becoming the R&D and manufacturing centre of choice for our customers.”
“The shifting financial, regulatory and globalization landscapes faced by medical devices manufacturers really call for a comprehensive business experience that can keep up with complexity, lower cost, quality, and compliance at once,” says Monica Menghini, executive vice president, Industry and Marketing, Dassault Systèmes. “Our new 'Licensed to Cure' industry solution experience is exactly meeting this challenge by allowing companies like Olympus Technologies Singapore to manage their business objectives in a complex regulatory environment while meeting consumers’ expectations for safe products.”